Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that debentureholders have converted $1.4 million of principal into common shares at $0.32 per share, issuing 4,375,000 common shares. This conversion represents a 35% reduction in the company's outstanding debenture principal, which previously stood at $4 million.
The conversion is a strategic move to strengthen Ocumetics' balance sheet as it approaches critical milestones in its ongoing patient study program. By converting debt into equity, the company reduces its interest obligations and enhances financial flexibility. President and CEO Dean Burns stated, "These debenture conversions reflect the confidence our investors and debenture holders continue to show in Ocumetics and our long-term vision."
The strengthened balance sheet positions Ocumetics to focus on advancing its first-in-human early feasibility study for a dynamic intraocular lens designed to restore natural vision without corrective lenses. The company is also preparing for an Investigational Device Exemption (IDE) submission to the U.S. Food and Drug Administration, a key regulatory step.
Ocumetics' technology aims to eliminate the need for glasses or contact lenses by allowing the eye's natural muscle activity to shift focus from distance to near. This innovation, if successful, could transform the ophthalmic industry by providing clear vision at all distances without perceptible time lag.
The conversion aligns investor interests with the company's clinical development objectives and reduces ongoing interest costs. As Ocumetics progresses toward its next milestones, the improved financial position may support further research and development activities.
For more information about Ocumetics and its technology, visit the company's profile on TSX Venture Exchange or its corporate website.
